25.70

1.98% -0.52

After Hours: 25.70

Alto Neuroscience Inc (ANRO)

Overview News Price History Discussions Forecast

Alto Neuroscience Inc stock is traded at $25.70, with a volume of 662.94K. It is down -1.98% in the last 24 hours and up +40.74% over the past month. Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Previous Close:

$26.22

Open:

$26.25

24h Volume:

662.94K

Relative Volume:

1.58

Market Cap:

$901.91M

Revenue:

Net Income/Loss:

$-74.31M

P/E Ratio:

-10.36

EPS:

-2.4817

Net Cash Flow:

$-62.86M

1W Performance:

-2.61%

1M Performance:

+40.74%

6M Performance:

+60.62%

1Y Performance:

+1,027%

1-Day Range:

$24.30

$26.77

1-Week Range:

$24.30

$26.98

52-Week Range:

$2.29

$28.44

Alto Neuroscience Inc Stock (ANRO) Company Profile

Name

Alto Neuroscience Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

773-255-5012

Address

650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

ANRO's Discussions on Twitter

Compare ANRO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANRO Alto Neuroscience Inc	25.70	920.16M	0	-74.31M	-62.86M	-2.4817
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Resumed	Chardan Capital Markets	Buy
Nov-17-25	Initiated	BTIG Research	Buy
Sep-29-25	Initiated	Chardan Capital Markets	Buy
Oct-23-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Oct-23-24	Downgrade	Wedbush	Outperform → Neutral
Sep-03-24	Initiated	Wedbush	Outperform
Feb-27-24	Initiated	Jefferies	Buy
Feb-27-24	Initiated	Robert W. Baird	Outperform
Feb-27-24	Initiated	Stifel	Buy
Feb-27-24	Initiated	TD Cowen	Outperform
Feb-27-24	Initiated	William Blair	Outperform

View All

Alto Neuroscience Inc Stock (ANRO) Latest News

Jul 05, 2026

Alto Neuroscience (ANRO) Edges Lower as Shares Test Key Support ZoneEquity Put Call - dars.gov.et

Jul 05, 2026

Jul 04, 2026

ANROAlto Neuroscience Inc Latest SEC Filings - Finviz

Jul 04, 2026

Jul 03, 2026

Price to earnings forward of Alto Neuroscience, Inc. – NYSE:ANRO - TradingView

Jul 03, 2026

Alto Neuroscience Announces Participation in Upcoming Investor Conferences - The National Law Review

Jul 03, 2026

Jul 02, 2026

Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? - Yahoo Finance

Jul 02, 2026

ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits

Jul 02, 2026

Jul 01, 2026

5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey

Jul 01, 2026

Jun 29, 2026

Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026